NCT01139138 - Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

August 31, 2015

Study Completion Date

June 30, 2017

Conditions

Colorectal CancerColorectal CarcinomaColorectal TumorsNeoplasms, Colorectal

Interventions

DRUG

Panitumumab

Panitumumab 6mg/kg IV every 14 days

DRUG

Irinotecan

Irinotecan 200mg/m2 IV every 14 days

DRUG

Everolimus

Everolimus daily po (dosage varies with cohort)

Trial Locations (1)

The Queen Elizabeth Hospital, Adelaide